======= CSRP2BP ======= == Gene Information == * **Official Symbol**: KAT14 * **Official Name**: lysine acetyltransferase 14 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=57325|57325]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9H8E8|Q9H8E8]] * **Interactions**: [[https://thebiogrid.org/search.php?search=CSRP2BP&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CSRP2BP|Open PubMed]] * **OMIM**: [[https://omim.org/entry/617501|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. May function as a scaffold for the ATAC complex to promote ATAC complex stability. Has also weak histone acetyltransferase activity toward histone H4. Required for the normal progression through G1 and G2/M phases of the cell cycle. {ECO:0000269|PubMed:19103755}. |Acetyltransf 1| |LIM domain binding| |Ada2/Gcn5/Ada3 transcription activator complex| |histone H3 acetylation| |histone acetyltransferase activity| |histone acetylation| |internal peptidyl-lysine acetylation| |peptidyl-lysine acetylation| |internal protein amino acid acetylation| |G2/M transition of mitotic cell cycle| |cell cycle G2/M phase transition| |protein acetylation| |protein acylation| |mitotic cell cycle phase transition| |cell cycle phase transition| |peptidyl-lysine modification| |histone modification| |covalent chromatin modification| |mitotic cell cycle process| |mitotic cell cycle| |chromatin organization| |peptidyl-amino acid modification| |cell cycle process| |chromosome organization| |cell cycle| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp390|Pifithrin-alpha 20μM R07 exp390]]|-2.05| |[[:results:exp281|Disulfiram 4.3μM R06 exp281]]|-1.94| |[[:results:exp42|BI-6727 0.001μM R01 exp42]]|-1.74| |[[:results:exp243|S-trityl-L-cysteine 0.5μM R05 exp243]]|-1.73| |[[:results:exp512|Olaparib 4μM R08 exp512]]|1.79| |[[:results:exp505|ML-792 0.2μM R08 exp505]]|1.82| |[[:results:exp134|MS023 2μM R03 exp134]]|1.97| |[[:results:exp135|MS023 7μM R03 exp135]]|2.69| ^Gene^Correlation^ |[[:human genes:z:zzz3|ZZZ3]]|0.475| |[[:human genes:m:mbip|MBIP]]|0.461| |[[:human genes:t:tada2a|TADA2A]]|0.413| Global Fraction of Cell Lines Where Essential: 0/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 2973 * **Expression level (log2 read counts)**: 5.23 {{:chemogenomics:nalm6 dist.png?nolink |}}